Using umbilical cord stem cells to treat end-stage liver disease
Efficacy and Safety of Different Dosage of Umbilical Cord-mesenchymal Stem Cells Through Peripheral Vein in Patients with End-stage Liver Diseases
This study is testing if umbilical cord stem cells can help people with severe liver disease feel better and avoid needing a liver transplant.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 22 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | General Hospital of Shenyang Military Region Academic / other |
| Locations | 1 site (Shenyang, Liaoning) |
| Trial ID | NCT06167473 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the efficacy and safety of umbilical cord-mesenchymal stem cells as a treatment for patients with end-stage liver disease. A total of 22 participants will be enrolled and randomly assigned to receive either a low or medium-high dose of stem cells infused through a peripheral vein. The study will monitor various liver function parameters and scores at multiple time points post-infusion to assess treatment outcomes. The aim is to provide an alternative to liver transplantation, which is limited by donor availability and complications.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18-80 diagnosed with end-stage liver disease who can provide informed consent.
Not a fit: Patients with liver tumors, those who have undergone liver transplantation, or individuals with serious cardiopulmonary diseases will not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could offer a new therapeutic option for patients suffering from end-stage liver disease.
How similar studies have performed: While stem cell therapies for liver diseases are being explored, this specific approach using umbilical cord-mesenchymal stem cells is relatively novel and has not been extensively tested in similar trials.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. 18-80 years old 2. End-stage liver disease 3. Sign informed consent Exclusion Criteria: 1. Tumours of the liver or other organs 2. Liver transplantation recipients 3. Acute myocardial infarction, acute heart failure, type I and type II respiratory failure, pulmonary embolism, acute cerebral infarction, acute cerebral haemorrhage and other serious cardiopulmonary diseases 4. Other diseases that may seriously affect the survival 5. Human immunodeficiency syndrome 6. Interferon or glucocorticoid therapy within 1 year 7. Treated for mental illness 8. Participation in other clinical trials within 30 days 9. Pregnant or breastfeeding subjects 10. Allergic asthma, allergic urticaria, eczema, or a history of multiple drug and food allergies 11. Other circumstances that are unsuitable for participation in this study
Where this trial is running
Shenyang, Liaoning
- General Hospital of Northern Theater Command — Shenyang, Liaoning, China (Recruiting)
Study contacts
- Principal investigator: Mengfan Ruan, MM — The General Hospital of Northern Theater Command
- Study coordinator: Xingshun Qi, MD
- Email: xingshunqi@126.com
- Phone: 18909881019
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.